Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for patients with prostate─...
Enterprise Therapeutics Competitors or Alternatives
Enterprise Therapeutics's top competitors include Synairgen, Verona Pharma and Aerogen.
Enterprise Therapeutics VS Synairgen
Synairgen is the biggest rival of Enterprise Therapeutics. Synairgen is headquartered in Southampton, England, and was founded in 2003. Like Enterprise Therapeutics, Synairgen also operates in the Pharmaceuticals space. Synairgen generates 632% the revenue of Enterprise Therapeutics.
Enterprise Therapeutics VS Verona Pharma
Verona Pharma is Enterprise Therapeutics's #2 competitor. Verona Pharma is a Public company that was founded in London, England in 2005. Like Enterprise Therapeutics, Verona Pharma also works within the Pharmaceuticals sector. Verona Pharma has 199 more employees vs. Enterprise Therapeutics.
Looking for similar companies to Enterprise Therapeutics?
Similar Companies
Biotechnology companies in Brighton
See 10 companies
Companies in Brighton with employees in 1-25 rangeSee 325 companies
Pharmaceuticals & Biotechnology companies in BrightonSee 14 companies
Pharmaceuticals companies in EnglandSee 640 companies
Companies in Brighton with revenue in $100K-5.0M rangeSee 641 companies
Biotechnology companies in EnglandSee 802 companies
Pharmaceuticals & Biotechnology companies in EnglandSee 1,390 companies
Biotechnology companies in United KingdomSee 1,665 companies
Pharmaceuticals companies in United KingdomSee 1,847 companies
Trending News for Enterprise Therapeutics and Enterprise Therapeutics's Competitors
AstraZeneca's Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...
FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma. ...
Novartis has scored a win in Korea's reimbursement system, clearing its immunosuppressant Cosentyx (secukinumab) for use in children and teens with chr...
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of care in certain NSCLC pati...
AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its oncology therapies, Imfinzi an...
DelveInsight's " Cancer Monoclonal Antibodies Market Insights, Competitive Landscape, and Market Forecast-2030 " report provides a comprehensive analys...
Global chronic disease management market is estimated to be valued at USD 6.49 Bn in 2025 and is expected to reach USD 15.85 Bn by 2032, exhibiting a c...
Frequently Asked Questions about Enterprise Therapeutics
Who are Enterprise Therapeutics's top competitors?
Enterprise Therapeutics's top 3 competitors are Synairgen, Verona Pharma, Aerogen.Who is similar to Enterprise Therapeutics?
Synairgen is the most similar to Enterprise Therapeutics. Verona Pharma and Aerogen are also similar to Enterprise Therapeutics.
Are Enterprise Therapeutics and Synairgen competitors?
Yes, Synairgen is one of Enterprise Therapeutics’s top competitors.